1-(4-Methylpiperidin-1-yl)pentan-1-one | 57150-32-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(4-Methylpiperidin-1-yl)pentan-1-one
• CAS: 57150-32-0
• 化学式: C₁₁H₂₁NO
• 分子量: 183.29
• InChiKey: WYZKREZWXXWGCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS<br/>[FR] COMPOSÉS UTILES POUR LE TRAITEMENT DE TROUBLES DU TRACTUS DIGESTIF
  申请人：ARDELYX INC

  公开号：WO2018129552A1

  公开（公告）日：2018-07-12

  The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist- induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

  本公开涉及化合物和治疗与液体潴留或盐过多有关的疾病的方法，例如心力衰竭（特别是充血性心力衰竭）、慢性肾病、晚期肾病、肝病和过氧化物酶体增殖物激活受体（PPAR）γ激动剂诱导的液体潴留。本公开还涉及化合物和治疗高血压的方法。本公开还涉及化合物和治疗胃肠道疾病的方法，包括治疗或减轻与胃肠道疾病相关的疼痛。
• [DE] SUBSTITUIERTE ARYLSULFONAMIDE, IHRE HERSTELLUNG UND IHRE VERWENDUNG ALS THROMBIN-HEMMENDE ARZNEIMITTEL<br/>[EN] SUBSTITUTED ARYLSULFONAMIDES, THEIR PREPARATION AND USE AS THROMBIN-INHIBITING MEDICAMENTS<br/>[FR] ARYLSULFONAMIDES SUBSTITUES, LEUR PREPARATION ET LEUR UTILISATION COMME MEDICAMENTS INHIBITEURS DE LA THROMBINE
  申请人：DR. KARL THOMAE GMBH

  公开号：WO1996002517A1

  公开（公告）日：1996-02-01

  (DE) Die vorliegende Erfindung betrifft neue substituierte Arylsulfonamide der allgemeinen Formel (I), in der A und R1 bis R8 wie im Anspruch 1 definiert sind, deren Stereoisomere, deren Gemische und deren Salze, insbesondere deren physiologisch verträgliche Salze mit anorganischen oder organischen Säuren oder Basen, welche wertvolle pharmakologische Eigenschaften aufweisen, insbesondere eine Thrombin-hemmende und die Thrombinzeit verlängernde Wirkung, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und deren Herstellung.(EN) New substituted arylsulfonamides are disclosed having the general formula (I), in which A and R1 to R8 have the definition given in the first claim, as well as their stereoisomers, their mixtures and their salts, in particular their physiologically acceptable salts with inorganic or organic acids or bases. These compounds have valuable pharmacological properties, in particular a thrombin-inhibiting effect and a thrombin-retarding effect. Also disclosed are medicaments containing these compounds, their use and their preparation.(FR) L'invention concerne de nouveaux arylsulfonamides substitués répondant à la formule générale (I), dans laquelle A et les groupes R1 à R8 ont la définition donnée dans la première revendication, leurs stéréoisomères, leurs mélanges et leurs sels, notamment leurs sels physiologiquement acceptables avec des acides ou des bases organiques ou inorganiques. Ces composés ont de précieuses propriétés pharmacologiques, notamment un effet inhibiteur et un effet retardateur de la thrombine. L'invention concerne également des médicaments contenant ces composés, leur utilisation et leur préparation.

  以下是一段经翻译的中文文本： (德语)此发明涉及取代的环硫酰胺，其通式(I)中，A和R1至R8如第一要求所定。它们的立体异构体、混合物及其盐类，尤其是特别药代使用其与无机或有机酸或碱的盐，此类化合物具有很重要的药理性质，尤其是对血小板的抑制作用使血小板凝集延缓，此外还包括含有此类化合物的药品，其使用及制备方式。 (英文)New substituted arylsulfonamides are disclosed having the general formula (I), in which A and R1 to R8 have the definition given in the first claim, as well as their stereoisomers, their mixtures and their salts, in particular their physiologically acceptable salts with inorganic or organic acids or bases. These compounds have valuable pharmacological properties, in particular a thrombin-inhibiting effect and a thrombin-retarding effect. Also disclosed are medicaments containing these compounds, their use and their preparation. (法语)此发明涉及取代的环硫酰胺，其通式(I)中，A和R1至R8如第一要求所定。它们的立体异构体、混合物及其盐类，尤其是特别药代使用其与无机或有机酸或碱的盐，此类化合物具有很重要的药理性质，尤其是对血小板的抑制作用使血小板凝集延缓，此外还包括含有此类化合物的药品，其使用及制备方式。
• COMPOSITIONS AND METHODS FOR TREATING CANCER
  申请人：The Regents of the University of California

  公开号：US20190119295A1

  公开（公告）日：2019-04-25

  K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.